United States· US:75987-150_ec8e46bc-7edf-405d-8c8e-2b2f7042fcb5
UPLIZNA
A inebilizumab product containing inebilizumab, registered in United States by Horizon Therapeutics USA, Inc.. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Inebilizumab is registered in 8 of 19 countries.
Countries holding a registration under ATC L04AG10 (inebilizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Inebilizumab · ATC L04AG10
8 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- Norwayprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- INEBILIZUMAB
- Manufacturer
- Horizon Therapeutics USA, Inc.
- Country
- United States (US)
- ATC code
- L04AG10
- ATC class
- Inebilizumab
- Defined daily dose
- 1.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1175987-150-03
- ndc1175987150033 VIAL, SINGLE-DOSE in 1 CARTON (75987-150-03) / 10 mL in 1 VIAL, SINGLE-DOSE (75987-150-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
51 interactions on record for inebilizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Inebilizumab · interactions on record
51 records
- 27 severe
- 18 moderate
- 6 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Inebilizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumUplizna 100 mgAmgen Europe
- CanadaUPLIZNAAMGEN CANADA INC
- SwitzerlandUplizna 100 mg/10ml, Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaUPLIZNAAmgen Europe B.V., Breda
- SpainUPLIZNA 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandUpliznaAmgen Europe B.V.
- FranceUPLIZNA 100 mg, solution à diluer pour perfusionAMGEN EUROPE
- IrelandUplizna 100 mg concentrate for solution for infusionAmgen Europe B.V.,
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Uplizna
- Norway · Uplizna
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2c8b74c-8876-4bd4-81ad-4838d6836fee GET /v1/drugs/e2c8b74c-8876-4bd4-81ad-4838d6836fee?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "10",
"substance": "INEBILIZUMAB",
"productndc": "75987-150",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761142",
"marketing_category": "BLA"
}See everything about inebilizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.